Main Conference Day 2 - JT (Japan Time, GMT+09:00)
- Jais Bjelke - Principal Scientist, Novo Nordisk, Norway
- Ben Ayers, DPhil - Vice President, Antibody-Drug Conjugates, Hummingbird Bioscience, Singapore
- Jyothsna Visweswaraiah - Senior Director, Drug Creation, Seismic Therapeutics, USA
- Masayuki Tsuchiya - President, CEO, Complecure, Inc., Japan
- Matthew Hardy - Associate Director, Recombinant Proteins, CSL Research, CSL, Australia
- Jan Terje Andersen - Professor, Biomedical Innovation, University of Oslo and Oslo University Hospital, Norway
- Starlynn Clarke - Senior Director, Preclinical Biology, Rondo Therapeutics, USA
- Daniel Simão - Head of the Bayer Pharma Lab, iBET – Instituto de Biologia Experimental e Tecnológica, Portugal
- Vladimir Bobkov, PhD - Principal Scientist, argenx, Belgium
- Maximilian Brinkhaus - Senior Scientist II, argenx, Belgium
Nona Biosciences is a global TechBio company committed to cutting-edge technology innovation and provides a total solution from ideation through IND filing (I to I®), spanning target validation and antibody discovery to preclinical research. Powered by fully human antibodies from the H2L2 and HCAb Harbour Mice® platform that generate IgG and VH only HCAb antibodies, respectively, and Hu-mAtrIx™, an AI-enhanced discovery and development platform, Nona is uniquely positioned to realize next generation antibody-based therapeutics across a range of formats and modalities. This presentation spans the breath of these modality solutions, from plug-and-play immune cell engager engineering with the HBICE® platform; bispecific design of blood-brain-barrier penetrant shuttles for CNS delivery; activity-based CAR candidate selection with NonaCarFx™; customized linker-drug design and tailored engineering for antibody–drug, antibody–oligonucleotide and radionuclide–drug conjugates (ADCs, AOCs and RDCs); and nanoparticle-based therapeutics such as mRNA-LNPs. With integrated preclinical IND enabling capabilities including toxicology and CMC, and 10+ IND approvals, Nona is ideally positioned to accelerate development of the next generation of antibody-based therapeutics.
- Sean Cullen - Director, Licensing and Corporate Strategy, Nona Biosciences